Gene expression profiling of de novo diffuse large B-cell lymphoma samples. Gene expression profiling of de novo diffuse large B-cell lymphoma samples

Gene expression profiling was performed for 7 DLBCL primary clinical samples and assignment of activated B-cell-like(ABC)/germinal center B-cell-like (GCB) DLBCL classes, B-cell-associated gene signature (BAGS), and a probability of response to vincristine was performed for each sample. Diffuse large B-cell lymphoma (DLBCL) is a very heterogeneous malignant disease with diverse clinical presentation, outcome, and pathogenic mechanism. In order to better risk stratify patients there is a current need to find and validate new biomarkers of the disease. An alternatively spliced transcript of NOTCH3 missing exon 16 was identified and displayed prognostic and predictive biomarker potential. Overall design: In total, 75 primary DLBCL samples were included in this study. Gene expression profiles were determined using Affymetrix GeneChip HG-U133 Plus 2.0 arrays. Gene expression of 7 samples were normalized together with expression from 68 DLBCL primary clinical samples that have been included in GSE74266 (n=47) and GSE109027 (n=21) and additional 16 other primary DLBCL samples, which has not been used further in this study.